Hinova Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 3
Founded: Sichuan China (2013)

Organization Overview

First Clinical Trial
2019
NCT03850795
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Hinova Pharmaceuticals Inc. | Hinova Pharmaceuticals USA, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

deuterated enzalutamide (2 trials)

enzalutamide (xtandi) (1 trial)

Drugs in Phase 1 Trials (1)

hp518 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prostatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3